Opendata, web and dolomites

iPSpine SIGNED

Induced pluripotent stem cell-based therapy for spinal regeneration

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iPSpine project word cloud

Explore the words cloud of the iPSpine project. It provides you a very rough idea of what is the project "iPSpine" about.

team    atmps    physiotherapy    ipsc    contributor    decreasing    socioeconomic    therapies    people    halt    technologies    socio    intervertebral    initiate    premature    aid    showcase    treatment    smart    contribution    innovation    despite    biology    pain    effort    translation    platforms    game    morbidity    burden    therapeutic    lasting    relief    extended    240    conservative    receive    lbp    patients    formed    radical    atmp    billion    option    back    40    worldwide    low    surgical    hereby    ambition    disciplinary    disability    reducing    proof    ipspine    date    treatments    translational    bedside    bottlenecks    leadership    led    quality    employing    least    intervention    unsatisfactory    pluripotent    costly    developmental    changing    profound    idd    invasive    accepted    million    tools    economic    therapy    existent    almost    life    medicinal    expertise    retirement    community    disc    strategy    biomaterials    left    bench    latter    stem    reverse    millions    medication    degeneration    cells    280   

Project "iPSpine" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 15˙396˙031 €
 EC max contribution 14˙959˙781 € (97%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 3˙522˙312.00
2    TECHNISCHE UNIVERSITEIT EINDHOVEN NL (EINDHOVEN) participant 1˙306˙771.00
3    UNIVERSITE DE NANTES FR (NANTES CEDEX 1) participant 1˙250˙312.00
4    SHEFFIELD HALLAM UNIVERSITY UK (SHEFFIELD) participant 1˙126˙572.00
5    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 867˙156.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 826˙617.00
7    NTRANS TECHNOLOGIES BV NL (UTRECHT) participant 770˙625.00
8    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 708˙710.00
9    PHARMALEX GMBH DE (FRIEDRICHSDORF) participant 676˙381.00
10    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) participant 671˙935.00
11    UNIVERSITA CAMPUS BIO MEDICO DI ROMA IT (ROMA) participant 557˙975.00
12    UNIVERSITAET ULM DE (ULM) participant 501˙583.00
13    AO-FORSCHUNGSINSTITUT DAVOS CH (DAVOS PLATZ) participant 491˙250.00
14    UNIVERSITAET BERN CH (BERN) participant 419˙000.00
15    UNIVERSITE DE MONTPELLIER FR (MONTPELLIER) participant 364˙903.00
16    SPINESERV GMBH & CO.KG DE (ULM) participant 321˙250.00
17    Catalyze B.V. NL (AMSTERDAM-DUIVENDRECHT) participant 251˙250.00
18    UNIVERSITY OF MIAMI US (CORAL GABLES MIAMI) participant 250˙175.00
19    STICHTING NATIONAAL REUMAFONDS NL (AMSTERDAM) participant 75˙000.00
20    THE UNIVERSITY OF HONG KONG HK (Pokfulam) participant 0.00

Map

 Project objective

Low back pain (LBP) is a leading cause of disability and morbidity worldwide. It is widely accepted that a major contributor to LBP is intervertebral disc degeneration (IDD). IDD account for at least 40% (~280 million) of all LBP cases, leading to an EU-economic burden of ~€240 billion. These patients receive conservative treatment (e.g. pain relief medication and physiotherapy). When the latter is unsatisfactory, the only option left are invasive and costly surgical intervention. To date, no treatments halt or reverse IDD. Despite the profound socioeconomic burden and impact of IDD, decreasing the quality of life of millions of people, a game-changing treatment strategy for IDD-induced LBP is almost non-existent. The iPSpine consortium was formed to initiate a European-led research effort to identify a future advanced therapeutic strategy that results into a radical new treatment of IDD-induced LBP. With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials. The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs. The iPSpine impact: iPSpine seeks to offer novel technologies and ATMPs for the advanced therapy research and development community. IDD will be the showcase, offering improved quality of life for millions of patients with IDD-induced LBP, through long-lasting reduction of LBP, reduced LBP-related premature retirement, and improved socio-economic contribution.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-10-08 17:18:36
Set up of Patient Advisory Board Documents, reports 2019-05-28 20:18:09
Guidelines and requirements for pre-in vivo evaluation of IVD advanced therapeutics Documents, reports 2019-05-28 20:18:09
Project website Websites, patent fillings, videos etc. 2019-05-28 20:18:09

Take a look to the deliverables list in detail:  detailed list of iPSpine deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Frances C. Bach, Kim M. Rooij, Frank M. Riemers, Joseph W. Snuggs, Willem A. M. Jong, Ying Zhang, Laura B. Creemers, Danny Chan, Christine Le Maitre, Marianna A. Tryfonidou
Hedgehog proteins and parathyroid hormone‐related protein are involved in intervertebral disc maturation, degeneration, and calcification
published pages: , ISSN: 2572-1143, DOI: 10.1002/jsp2.1071
JOR SPINE 2/4 2020-01-29
2019 Daniela A. Frauchiger, Adel Tekari, Rahel D. May, Emina Džafo, Samantha C.W. Chan, Jivko Stoyanov, Alessandro Bertolo, Xingshuo Zhang, Julien Guerrero, Daisuke Sakai, Jordy Schol, Sibylle Grad, Marianna Tryfonidou, Lorin M. Benneker, Benjamin Gantenbein
Fluorescence-Activated Cell Sorting Is More Potent to Fish Intervertebral Disk Progenitor Cells Than Magnetic and Beads-Based Methods
published pages: 571-580, ISSN: 1937-3384, DOI: 10.1089/ten.tec.2018.0375
Tissue Engineering Part C: Methods 25/10 2020-01-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPSPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPSPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More